Pentoxifylline for Non-Alcoholic Fatty Liver Disease
Author Information
Author(s): Li Wenjun, Zheng Liu, Sheng Chunjun, Cheng Xiaoyun, Qing Liu, Qu Shen
Primary Institution: Shanghai Tenth People's Hospital, Tongji University School of Medicine
Hypothesis
Can pentoxifylline effectively treat patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)?
Conclusion
Pentoxifylline reduces AST and ALT levels and may improve liver histological scores in patients with NAFLD/NASH, but does not appear to affect cytokines.
Supporting Evidence
- Pentoxifylline-treated patients showed a significant decrease in AST and ALT levels compared to control groups.
- Two studies reported improvement in liver histology after treatment with pentoxifylline.
- Adverse events were reported in some studies, but pentoxifylline was generally well tolerated.
Takeaway
Pentoxifylline is a medicine that helps lower liver enzyme levels in people with fatty liver disease, but it doesn't change certain inflammation markers.
Methodology
The review included six studies, two randomized controlled trials and four prospective cohort studies, analyzing the effects of pentoxifylline on liver enzymes and histology.
Potential Biases
The overall methodological quality of the studies was relatively weak, with potential biases due to the nature of the study designs.
Limitations
The studies had small sample sizes and inconsistent reporting of outcomes.
Participant Demographics
Patients included were aged 18 to 70 years, with biopsy-proven NASH or NAFLD.
Statistical Information
P-Value
0.01 for AST, 0.03 for ALT
Confidence Interval
95% CI -10.78 to -1.44 for AST, 95% CI -12.26 to 0.62 for ALT
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website